Use of posaconazole delayed-release tablets for treatment of invasive aspergillosis

Mycoses. 2015 May;58(5):313-4. doi: 10.1111/myc.12309. Epub 2015 Feb 27.


A 65-year-old man developed Aspergillus brain abscesses following surgical resection of a sinus aspergilloma. He was treated with voriconazole for 1 year but infection recurred. We elected to treat with posaconazole delayed-release tablets, currently only indicated as antifungal prophylaxis in high-risk patients. A maintenance dose of 300 mg Q24 h resulted in a therapeutic serum concentration and appears safe and clinically effective thus far. This is the first report of successful use of posaconazole tablets for treatment of invasive aspergillosis.

Keywords: Posaconazole; antifungal therapy; aspergillus; invasive mould infection.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antifungal Agents / administration & dosage*
  • Antifungal Agents / blood
  • Brain / microbiology
  • Brain Abscess / drug therapy*
  • Delayed-Action Preparations / administration & dosage
  • Humans
  • Male
  • Neuroaspergillosis / drug therapy*
  • Tablets
  • Treatment Outcome
  • Triazoles / administration & dosage*
  • Triazoles / blood
  • Voriconazole / therapeutic use


  • Antifungal Agents
  • Delayed-Action Preparations
  • Tablets
  • Triazoles
  • posaconazole
  • Voriconazole